注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Adverum Biotechnologies Inc是一家临床阶段的基因治疗公司。该公司针对眼部和罕见疾病未满足的医疗需求。该公司开发候选基因治疗产品。其主要候选产品ADVM-022是一种单一的办公室内玻璃体内(IVT)注射基因治疗产品,旨在提供与持续治疗反应相关的长期持久水平的aflibercept,减少与频繁注射抗血管内皮生长因子(VEGF)相关的治疗负担和黄斑液波动。ADVM-022正被开发用于治疗对抗VEGF治疗有反应的湿性年龄相关性黄斑变性(湿性AMD)患者。该公司的第二个候选产品ADVM-062(AAV.7m8-L-opsin)是一种正在开发的基因治疗候选产品,旨在通过单次IVT注射将OPN1LW基因的功能拷贝传递给monochromacy(BCM)患者的中央凹锥体。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
C. Patrick Machado | 59 | 2017 | Independent Chairman |
Dawn A. Svoronos | 70 | 2020 | Independent Director |
James Paul Scopa | 64 | 2019 | Independent Director |
Laurent Fischer | 59 | 2020 | President, CEO & Director |
Szilard Kiss | - | - | Scientific Advisory Board Member |
Mark L. Lupher | 52 | 2019 | Independent Director |
Soo J. Hong | 51 | 2022 | Independent Director |
Reed Vaughn Tuckson | 72 | 2021 | Independent Director |
Scott M. Whitcup | 64 | 2020 | Independent Director |
David S. Boyer | - | - | Scientific Advisory Board Member |
Arshad M. Khanani | - | - | Scientific Advisory Board Member |
Charles C. Wykoff | - | - | Scientific Advisory Board Member |
Rabia Gurses Ozden | 55 | 2022 | Independent Director |
Jeffrey S. Heier | 62 | - | Scientific Advisory Board Member |
C. David Nicholson | 68 | 2023 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核